The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

Both winter and spring camelina might be on the cusp of better varieties to help boost production of the oilseed in Western ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual ...

The study reveals that AI systems offer promising accuracy in predicting treatment outcomes, particularly when used to ...

该研究首次揭示天然炔酮化合物SL-001通过抑制Polθ介导的替代性 DNA 修复通路，在HRD 肝癌 细胞中引发合成致死效应，为肝癌精准治疗提供全新靶点。 肝癌是全球第二大癌症死亡原因，其中肝细胞癌 (HCC)占80%以上。尽管手术、放疗和靶向治疗 ...

During meiosis, at least one crossover is selectively generated per pair of homologous chromosomes through homologous recombination to ensure their faithful segregation. The molecular mechanisms ...

That’s where the team expects gene editing to come in. They will use a technique called “homologous recombination,” which causes a recombination between chromosomes of different sub-genomes. They will ...

April 9, 2025 First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations ...

Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea ...